Evonik Bolsters Excipients Portfolio

Evonik has signed an agreement to acquire the Lactel business of biodegradable polymers from Durect Corporation $15 million. The transaction is expected to close by the first quarter of 2021. An offer will be extended to each of the 15 employees of Durect located in Birmingham, AL, which are associated with the Lactel business to transition to the Evonik.

“The acquisition of the Lactel business will strengthen both our innovation growth field Healthcare Solutions and Evonik’s position as a globally leading CDMO for drug delivery solutions,” said Johann-Caspar Gammelin, head of the nutrition and care division of Evonik. “The acquisition of the Lactel business marks a consequential step in the growth agenda of the life-science division Nutrition & Care. The Lactel business will benefit from fast-growing markets such as advanced drug delivery, biomaterials for tissue engineering, and the 3D printing of implantable medical devices.”

James E. Brown, president and chief executive officer, Durect Corporation, said, “It has been a pleasure working with the highly motivated and talented Lactel team. We have confidence that Evonik will apply its resources and commitment to excellence to enable the Lactel product line and supporting team members to thrive. With Evonik’s global reach, existing and new customers will benefit from tapping into Health Care’s twelve global laboratories staffed with formulation, application and regulatory experts to assist in bringing their products faster to the market.”

“The integration of the Lactel business into Evonik’s market-leading portfolio of functional excipients, biomaterials and integrated CDMO services will strengthen our position as a preferred development partner and solutions provider for pharmaceutical and medical device customers,” said Thomas Riermeier, head of the Evonik’s health care business line. “By welcoming Lactel and members of their team into the Evonik family, we look forward to providing customers with even greater platform versatility as well as other value-adding services.”

Poly(lactide-co-glycolide) (PLG or PLGA) polymers are widely used as a functional excipient to control the release of parenteral drug products. They are also utilized to control the biodegradation of implantable medical devices across various orthopedic, cardiovascular, wound healing and other applications. Resomer and Lactel are two of the most preferred brands of standard and custom PLGA polymers.